Seahorse Bioscience

Boston, United States Founded: 2000 • Age: 26 yrs Acquired By Agilent
Cellular metabolic status is measured via the Seahorse XFp Analyzer.
Request Access

About Seahorse Bioscience

Seahorse Bioscience is a company based in Boston (United States) founded in 2000 was acquired by Agilent in September 2015.. Seahorse Bioscience has raised $34.85 million across 5 funding rounds from investors including FLIR, Agilent and Flagship Pioneering. Seahorse Bioscience operates in a competitive market with competitors including Alamar Biosciences, Glympse Bio, Harmonic Discovery, Cellarcus Biosciences and Luceome Biotechnologies, among others.

  • Headquarter Boston, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $34.85 M (USD)

    in 5 rounds

  • Latest Funding Round
    $11.35 M (USD), Series E

    Mar 29, 2013

  • Investors
    FLIR

    & 9 more

  • Employee Count
    Employee Count
  • Acquired by
    Agilent

    (Sep 09, 2015)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Seahorse Bioscience
Headcount 50-200
Employee Profiles 11
Board Members and Advisors 10
Employee Profiles
People
Padraig McDonnell
SVP & President & Chief Commercial Officer, Agilent CrossLab Group
People
Sam Raha
SVP, Agilent & President, Diagnostics & Genomics Group
People
Dominique Grau
SVP, Human Resources & Global Communications
People
Robert W. McMahon
SVP & CFO

Unlock access to complete

Funding Insights of Seahorse Bioscience

Seahorse Bioscience has successfully raised a total of $34.85M across 5 strategic funding rounds. The most recent funding activity was a Series E round of $11.35 million completed in March 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Series E — $11.3M
  • First Round

    (01 Mar 2002)

  • Investors Count 9
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2013 Amount Series E - Seahorse Bioscience Valuation

investors

Feb, 2010 Amount Series D - Seahorse Bioscience Valuation

investors

Mar, 2009 Amount Series D - Seahorse Bioscience Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Seahorse Bioscience

Seahorse Bioscience has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include FLIR, Agilent and Flagship Pioneering. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Tech & offline focused VC firm investing in early & growth stage startups in the US
Founded Year Domain Location
Private equity investments in life sciences businesses are managed.
Founded Year Domain Location
Early stage VC firm investing in the US and Korea
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Seahorse Bioscience

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Seahorse Bioscience

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Seahorse Bioscience Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Seahorse Bioscience

Seahorse Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alamar Biosciences, Glympse Bio, Harmonic Discovery, Cellarcus Biosciences and Luceome Biotechnologies, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Ultra-high sensitivity protein analysis solutions are provided across multiplex levels.
domain founded_year HQ Location
Multiple human diseases are monitored noninvasively through urine-based analysis.
domain founded_year HQ Location
Developer of kinase inhibitor drugs for oncology
domain founded_year HQ Location
Provider of extracellular vesicle analysis assay
domain founded_year HQ Location
Assay technology is developed for identifying drugs against kinases.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Seahorse Bioscience

Frequently Asked Questions about Seahorse Bioscience

When was Seahorse Bioscience founded?

Seahorse Bioscience was founded in 2000 and raised its 1st funding round 2 years after it was founded.

Where is Seahorse Bioscience located?

Seahorse Bioscience is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Is Seahorse Bioscience a funded company?

Seahorse Bioscience is a funded company, having raised a total of $34.85M across 5 funding rounds to date. The company's 1st funding round was a Series D of $6M, raised on Mar 01, 2002.

What does Seahorse Bioscience do?

Seahorse Bioscience has developed an instrument system, called the Seahorse XFp Analyzer to assay the metabolic status of cells by measuring the Oxygen Consumption Rate (OCR) - a measure of the cellular respiration, and extracellular acidification rate (ECAR) - a measure of the rate of glycolysis, at regular intervals (5-8 minutes) using solid state sensor probes. The OCRECAR measurements can be used as metabolic phenotypes in various cellular assays and diagnostic tests. The company has developed both the instrumentation, as well as reagents and consumables to be used for the assays on the Seahorse XFp Analyzer. The company was acquired by Agilent Technologies in September 2015, which currently manufactures and sells the instrument system.

Who are the top competitors of Seahorse Bioscience?

Seahorse Bioscience's top competitors include Alamar Biosciences, Glympse Bio and Harmonic Discovery.

Who are Seahorse Bioscience's investors?

Seahorse Bioscience has 10 investors. Key investors include FLIR, Agilent, Flagship Pioneering, Life Sciences Partners, and Commonwealth Capital Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available